BAM
PDSB icon

Belpointe Asset Management’s PDS Biotechnology PDSB Stock Holding History

Belpointe Asset Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-755
Closed -$4.64K – 2529
2023
Q1 		$4.64K Hold
755
– – ﹤0.01% 3041
2022
Q4 		$9.97K Buy
+755
New +$5.33K ﹤0.01% 2620

Other funds holding PDSB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Belpointe Asset Management's PDSB Position: Q2 2023 in Review

Belpointe Asset Management sold out of PDS Biotechnology (PDSB) in Q2 2023, closing a stake of 755 shares — an estimated $4.64K sold.

Belpointe Asset Management first reported a position in PDSB in Q4 2022 and held it in 2 quarters. The position peaked at $9.97K in Q4 2022. 80 funds tracked by Wall St. Rank hold PDSB as of Q2 2023.

  • Belpointe Asset Management reported no remaining PDS Biotechnology position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 755 PDS Biotechnology shares in Q2 2023, an estimated $4.64K.
  • Belpointe Asset Management first reported a position in PDS Biotechnology in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's PDS Biotechnology position peaked at $9.97K in Q4 2022.
  • 80 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.